Shots:

• COUR to receive ~$420M milestone and royalties on sales of licensed products. Takeda exercised its option to acquire the exclusive global license to develop and commercialize TAK-101/CNP-101 following P-IIa proof-of-concept placebo-controlled study
• In Dec’2015- Takeda and COUR collaborated to develop therapies for celiac disease- provided Takeda an exclusive option to acquire a WW license to the developed program and an option to collaborate up to three additional TIMP compounds
• CNP-101/TAK-101 is an investigational immune modifying nanoparticle designed to induce tolerance to gluten in patients with celiac disease. The P-IIa POC study results demonstrated mean change from baseline in IFN-γ ELISpotSFUs (2.10 vs 17.57)- protection from intestinal mucosal damage with deterioration (0.18 vs 0.63)

Click here to­ read full press release/ article 

 Ref: Takeda | Image: Takeda